Abstract 2364
Background
KEYNOTE-181 (NCT02564263) is an open-label, randomized, phase 3 trial of pembrolizumab (P) vs investigator’s choice of single-agent paclitaxel, docetaxel, or irinotecan (standard of care [SOC]) in advanced/metastatic AC or SCC of the esophagus. In the global cohort, P was superior to SOC for OS in pts with PD-L1 combined positive score (CPS) ≥10, with a more favorable safety profile. We present results of the China cohort.
Methods
Eligible pts were randomly assigned 1:1 to receive P 200 mg Q3W for up to 2 y or investigator’s choice of SOC. Randomization was stratified by histology (SCC vs AC) and region (Asia vs rest of world). Primary end points were OS in the intention-to-treat (ITT), SCC, and PD-L1 CPS ≥10 populations.
Results
Of the 123 Chinese pts enrolled, 119 had SCC and 54 had CPS ≥10. Pts were randomly assigned to receive P (62 pts; 60 had SCC; 25 had CPS ≥10) or SOC (61 pts; 59 had SCC; 29 had CPS ≥10). As of Feb 13, 2019, the median follow-up (from randomization, regardless of death) was 15.1 mo (P) vs 14.7 mo (SOC). Median OS was longer with P vs SOC overall (8.4 vs 5.6 mo; HR 0.55; 95% CI 0.36-0.82) and in the SCC (8.4 vs 5.6 mo; HR 0.55; 95% CI 0.37-0.83), and CPS ≥10 groups (12.0 vs 5.3 mo; HR 0.34; 95% CI 0.17-0.69). Median OS for P vs SOC in the CPS <10 group was 6.4 vs 6.1 mo (HR 0.72; 95% 0.43-1.21). OS rates at 12 mo for the P vs SOC groups were 36.3% vs 16.7% overall, 35.7% vs 15.3% in the SCC, and 53.1% vs 16.1% in the CPS ≥10 groups. PFS rates at 6 mo were similar for P vs SOC (26.4% vs 24.1% in the ITT group), but ORR was substantially higher (16.1% vs 3.3% in the ITT group). Median DOR was not reached for P (4.4+ to 14.6+ mo) and was 3.2 mo (2.6-3.9) for the SOC group. Fewer pts receiving P vs SOC had any-grade (76% vs 83%) or grade 3-5 (21% vs 42%) drug-related AEs or drug-related AEs that resulted in discontinuation (6.4% vs 11.9%).
Conclusions
P showed favorable OS, compared with SOC, as second-line therapy for AC/SCC in Chinese pts, with a more favorable safety profile. In China, more patients had SCC than AC and P showed clinically meaningful OS improvement regardless of PD-L1 status. This finding was consistent with that of the Asia group from the full global cohort.
Clinical trial identification
NCT02564263, September 30, 2015.
Editorial acknowledgement
Amy McQuay, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA), funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Legal entity responsible for the study
Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Funding
Merck Sharp & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
J. Zhang: Advisory / Consultancy: Bayer; Advisory / Consultancy: BMS; Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: Sanofi; Speaker Bureau / Expert testimony: Merck-Serono; Speaker Bureau / Expert testimony: Pfizer; Speaker Bureau / Expert testimony: Taiho; Speaker Bureau / Expert testimony: HengRui; Speaker Bureau / Expert testimony: Novartis. Y. Cui: Full / Part-time employment: MSD, China. P. Bhagia: Full / Part-time employment: Merck & Co., Inc. S.P. Kang: Full / Part-time employment: Merck & Co., Inc.; Shareholder / Stockholder / Stock options: Celgene; Shareholder / Stockholder / Stock options: Macrogenics; Shareholder / Stockholder / Stock options: Celldex; Shareholder / Stockholder / Stock options: Agenus; Shareholder / Stockholder / Stock options: Pharmacyclics; Shareholder / Stockholder / Stock options: Endocyte. W. Lu: Full / Part-time employment: MSD, China. Y. Zhou: Full / Part-time employment: MSD China. All other authors have declared no conflicts of interest.
Resources from the same session
1452 - RBP-Jκ in colon cancer cells facilitates tumor associated macrophages (TAMs)-induced cell metastasis by secreting CXCL11
Presenter: Meng jie Liu
Session: Poster Display session 2
Resources:
Abstract
2786 - Development of a living organoid biobank derived from colorectal cancer patients: towards personalized medicine
Presenter: Federica Papaccio
Session: Poster Display session 2
Resources:
Abstract
3351 - Microsatellite Instability Detection in Colorectal Cancer: 44-Center Comparison between the Idylla MSI Assay and Routine Molecular and Immunohistochemistry Tests on Formalin-Fixed Paraffin-Embedded Tissue
Presenter: Xavier Matias-guiu
Session: Poster Display session 2
Resources:
Abstract
4901 - Expression profile of EPHB3 and its prognostic significance in colorectal cancer progression (Running head: Prognostic value of EPHB3 in colorectal cancers)
Presenter: Bogun Jang
Session: Poster Display session 2
Resources:
Abstract
5030 - A pan-ErbB family inhibitor, AF8c, promotes apoptosis by DR5/Nrf2 activation via ROS in colorectal cancer cells
Presenter: Soyeon Jeong
Session: Poster Display session 2
Resources:
Abstract
5053 - Frequent BRAF, GNAS and SMAD4 mutations identified in Colorectal Mucinous Carcinomas
Presenter: Sun Mi Lee
Session: Poster Display session 2
Resources:
Abstract
5220 - Impact of CCL4 knockout using CRISPR Cas-9 technology on colorectal tumor progression
Presenter: Roba Barakat
Session: Poster Display session 2
Resources:
Abstract
5330 - Independent clinical validation of a gene expression profile to predict benefit of 5-FU in metastatic colorectal cancer
Presenter: Ida Buhl
Session: Poster Display session 2
Resources:
Abstract
5515 - WRN mutated Colorectal Cancer (CRC) is characterized by a distinct molecular and immunological profile
Presenter: Andreas Seeber
Session: Poster Display session 2
Resources:
Abstract
5716 - Mutation analysis of B2M gene in colorectal cancer patients with microsatellite instability
Presenter: Ivana Kašubová
Session: Poster Display session 2
Resources:
Abstract